发布时间:
2020
-
11
-
26
点击次数:
0
Positions：
Chief Business Officer
Company：
CStone Pharmaceuticals
个人简介：
Dr. Bing Yuan is currently Chief Strategy & Business Officer at CStone Pharmaceuticals. As a seasoned business executive in business development and commercial strategy, he has made significant contributions to 12 global oncology brands at various stages. He is currently responsible for corporate strategy, business development & alliance management, portfolio strategy & business insights, and R&D project management office at CStone. Previously, he had also established and managed a few other functions, including investor relations, government affairs, communications & PR, medical affairs and commercial team. Before joining CStone in 2016, he was Executive Director and Global Lead of Oncology BD at Merck (MSD). He focused on expanding Merck's leadership position in cancer immunotherapy, and successfully achieved 34 M&A, licensing and Keytruda collaboration deals. Before Merck, he was Global Head of Life Cycle Strategy and Executive Director at Novartis Oncology, responsible for Glivec and Afinitor brand life cycle strategy. He played a key role in global launch of Zykadia in ALK+ lung cancer and was a core deal team member for Jakavi, Mektovi and Tabrecta licensing deals. He was three-time Novartis Oncology President Award recipient. He also served as Global Oncology Marketing Lead at Eisai in the past, managing entire oncology portfolio. Dr. Yuan holds a Ph.D. in Molecular Biology from Columbia University, an MBA from Cornell University and B.S. of Biochemistry from Nanjing University.